精品人妻无码一区二区三区软件 ,麻豆亚洲AV成人无码久久精品,成人欧美一区二区三区视频,免费av毛片不卡无码

您現(xiàn)在的位置是:首頁SCI期刊CANCER BIOLOGY & THERAPY(癌癥生物學(xué)和治療)
CANCER BIOLOGY & THERAPY

CANCER BIOLOGY & THERAPY SCIE

癌癥生物學(xué)和治療

1538-4047

醫(yī)學(xué)

Monthly

No

CANCER BIOL THER

2002

123

UNITED STATES

http://www.tandfonline.com/loi/kcbt20#.V4he8kz9cSQ

平均2.3月審稿時(shí)間

約50%平均錄用比例

2.879影響因子

腫瘤學(xué)小學(xué)科

月期刊平臺(tái)服務(wù)過的文章錄用時(shí)間為1-3個(gè)月,依據(jù)20年經(jīng)驗(yàn),經(jīng)月期刊專家預(yù)審?fù)ㄟ^后的文章,投稿通過率100%以上!
SCI三劍客

中文簡(jiǎn)介

影響因子:3.294五年影響因子:3.380Thomson Reuters, Journal Citation Reports?for 2016將癌癥生物學(xué)和治療在217個(gè)腫瘤學(xué)領(lǐng)域中排名92位。目標(biāo)和范圍:癌癥是第二大致死原因,是一個(gè)由100多種疾病組成的異質(zhì)性群體。癌癥的特征是細(xì)胞和基質(zhì)細(xì)胞的無序和不受控制的增殖,伴隨著細(xì)胞死亡的減少,在營(yíng)養(yǎng)和生長(zhǎng)因子缺乏、缺氧和細(xì)胞間接觸減少的壓力下,細(xì)胞能夠存活。在分子水平上,癌癥是一種遺傳疾病,是由于體細(xì)胞隨時(shí)間積累突變而發(fā)展起來的。表型包括基因組不穩(wěn)定性和允許加速遺傳變化的染色體非整倍體。任何細(xì)胞的惡性轉(zhuǎn)化和腫瘤進(jìn)展都需要永生、檢查點(diǎn)失控、生長(zhǎng)失調(diào)和生存。關(guān)于伴隨腫瘤發(fā)展和進(jìn)展的大量細(xì)胞和分子遺傳變化以及宿主與腫瘤的相互作用已經(jīng)有了大量的了解。這是分子腫瘤學(xué)領(lǐng)域的目標(biāo),利用這一知識(shí)來了解癌癥的發(fā)病機(jī)制和藥物作用,以及開發(fā)更有效的癌癥診斷和治療策略。這包括預(yù)防策略以及治療轉(zhuǎn)移的方法。隨著人類基因組序列和基因組和蛋白質(zhì)組方法的可用性,大量的工具和資源正在產(chǎn)生更多的信息。挑戰(zhàn)在于從這些信息中找出生物學(xué)意義,建立適當(dāng)?shù)哪P秃图僭O(shè),并為臨床醫(yī)生和患者的利益翻譯信息?!栋┌Y生物學(xué)與治療》旨在發(fā)表關(guān)于癌癥分子基礎(chǔ)的原創(chuàng)研究,包括與診斷或治療相關(guān)的翻譯文章。我們將包括及時(shí)的評(píng)論涵蓋廣泛的期刊范圍。該雜志還將發(fā)表評(píng)論文章和感興趣的會(huì)議報(bào)告。其目標(biāo)是通過使用傳統(tǒng)和電子格式及時(shí)發(fā)表重要成果,促進(jìn)交流和迅速交換信息。該雜志和杰出的編輯委員會(huì)將努力保持在所有活動(dòng)的卓越的最高標(biāo)準(zhǔn),以產(chǎn)生寶貴的資源。

http://cbt.msubmit.net/cgi-bin/main.plex

英文簡(jiǎn)介

Impact Factor: 3.294Five-Year Impact Factor: 3.380? 2017 Thomson Reuters, Journal Citation Reports ? for 2016 ranks Cancer Biology & Therapy 92 out of 217 in Oncology.Aims & Scope: Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.

SCI服務(wù)流程
服務(wù)流程
常見問題
Q&A
醫(yī)學(xué)領(lǐng)域收錄的呼吸系統(tǒng)方面的期刊也是有很多的,而且尤其是SCI所收錄的優(yōu)秀刊物,備受不少相關(guān)醫(yī)學(xué)人員的喜愛,所
FACIAL PLASTIC SURGERY是SCI4區(qū)期刊。 FACIAL PLASTIC SURGERY期刊涉及的研究方向?yàn)獒t(yī)學(xué)領(lǐng)域。 關(guān)于《FACIAL PLASTIC SURGERY》雜志,下面
相信對(duì)于SCI論文的發(fā)表不少人是注重字?jǐn)?shù)要求的,一般所投稿期刊都會(huì)有明確的規(guī)定,但也有的作者想要了解一下 SCI論文
高分子一般指相對(duì)分子質(zhì)量高達(dá)幾千到幾百萬的化合物,絕大多數(shù)高分子化合物是許多相對(duì)分子質(zhì)量不同的同系物的混合

影響因子趨勢(shì)圖

SCI服務(wù)明細(xì)

醫(yī)學(xué)方向的SCI期刊推薦
R&J
大類學(xué)科同領(lǐng)域優(yōu)質(zhì)期刊 大類學(xué)科 小類學(xué)科 影響因子 分區(qū) ISSN
ACTA ONCOLOGICA 醫(yī)學(xué) 腫瘤學(xué) 3.298 3區(qū) 0284-186X
Advances in Cancer Research 醫(yī)學(xué) 腫瘤學(xué) 4.667 N/A 0065-230X
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 醫(yī)學(xué) 腫瘤學(xué) 3.015 N/A 0277-3732
ANNALS OF ONCOLOGY 醫(yī)學(xué) 腫瘤學(xué) 14.196 N/A 0923-7534
ANNALS OF SURGICAL ONCOLOGY 醫(yī)學(xué) 腫瘤學(xué) 3.681 N/A 1068-9265
ANTI-CANCER DRUGS 醫(yī)學(xué) 腫瘤學(xué) 1.801 N/A 0959-4973
ANTICANCER RESEARCH 醫(yī)學(xué) 腫瘤學(xué) 1.935 N/A 0250-7005
Asia-Pacific Journal of Clinical Oncology 醫(yī)學(xué) 腫瘤學(xué) 1.539 N/A 1743-7555
BMC CANCER 醫(yī)學(xué) 腫瘤學(xué) 2.933 N/A 1471-2407
Brachytherapy 醫(yī)學(xué) 腫瘤學(xué) 2.03 4區(qū) 1538-4721
在醫(yī)學(xué)領(lǐng)域中的兒科方向期刊是最不缺的,尤其是被SCI所收錄的期刊數(shù)量更是不在少數(shù),而要說錄用率高的,那么相對(duì)的...
急診醫(yī)學(xué)也是醫(yī)學(xué)領(lǐng)域較大的一方向,關(guān)于該期刊sci收錄的有不少,但要說1個(gè)月左右錄用的是有的,但并不是太多,畢竟...
sci醫(yī)學(xué)屬于一大分類,其下還有不少的小分類,如免疫學(xué)、病理學(xué)、內(nèi)科醫(yī)學(xué)等。所以sci二區(qū)醫(yī)學(xué)期刊是有很多的,可以...
醫(yī)學(xué)綜述的查重率控制在多少為宜? 醫(yī)學(xué)綜述的查重率控制標(biāo)準(zhǔn) 因期刊等級(jí)和學(xué)術(shù)要求的不同而有所差異 。一般來說,...
在醫(yī)學(xué)領(lǐng)域中過敏學(xué)這一方向可發(fā)文章的醫(yī)學(xué)人員也是不少的,當(dāng)然對(duì)于期刊的選擇上肯定是重中之重了。所以這里為相...
在醫(yī)學(xué)領(lǐng)域中的腫瘤學(xué)這一研究方向的文章,無論是寫作還是發(fā)表上都是較為不容易的,尤其還是對(duì)于期刊的選擇上,大...
世界外科腫瘤學(xué)雜志是SCI嗎?經(jīng)查詢可知, 《世界外科腫瘤學(xué)雜志》是SCI ,英文名為World Journal of Surgical Oncology,目前為中...
在醫(yī)學(xué)領(lǐng)域中腫瘤學(xué)這一方向涉及的位置也是尤為重要的,不少相關(guān)科室的醫(yī)學(xué)人員發(fā)表論文,而在期刊上的選擇上就尤...

發(fā)現(xiàn)心儀選題請(qǐng)?zhí)顔?/b>

獲取發(fā)表周期短、審稿速度快容易錄用的期刊